“Making TauRx’s groundbreaking drug HMTM# accessible
to patients with Alzheimer's Disease under Named Patient Program”
HKU AIDS Institute & Immuno Cure’s Collaborative Therapeutic HIV Vaccine Research Project secured HK$66.7m TRS funding from Research Grant Council
Learn MoreImmuno Cure Successfully Admitted into the HKSTP Elite Programme
Learn MoreImmuno Cure’s Anti-Δ42PD1 Antibody Project Awarded HKSAR Government’s RAISe+ Scheme Funding
Learn MorePoredeen Appoints ICB as Exclusive Named Patient ProgramManager for HMTM# in Hong Kong and Macau
Immuno Cure Completed US$12M First Close of Series A Financing, led by AEF GBA Fund managed by Gobi Partners GBA
Closed the US$12 million tranche in the US$27 million Series A fundraising round. Led by the AEF Greater Bay Area Fund that Gobi Partners GBA manages, this round will be used to accelerate the development of DNA vaccines and antibodies, as well as to prepare for an initial public offering (“IPO”) in Hong Kong.
Immuno Cure Kicks off Phase IIa Clinical Trial in Hong Kong
The initiation of a Phase IIa clinical trial of ICCOV, a COVID-19 DNA vaccine candidate. The clinical trial is initiated by Immuno Cure in collaboration with the University of Hong Kong (“HKU”) and will be conducted in Gleneagles Hospital Hong Kong.